2511-97-9Relevant academic research and scientific papers
NOVEL GLYCINE TRANSPORT INHIBITORS FOR THE TREATMENT OF PAIN
-
Page/Page column 54; 55, (2018/08/12)
The present invention relates to novel glycine transport inhibitor compounds and their use for treating pain.
IMMUNOTHERAPEUTIC AGENT
-
Paragraph 0101-0102, (2018/07/29)
Compounds for use in the treatment of sepsis and/or the prevention or treatment of post-sepsis syndrome.
Synthesis and Characterization of Novel Acyl-Glycine Inhibitors of GlyT2
Mostyn, Shannon N.,Carland, Jane E.,Shimmon, Susan,Ryan, Renae M.,Rawling, Tristan,Vandenberg, Robert J.
, p. 1949 - 1959 (2017/09/26)
It has been demonstrated previously that the endogenous compound N-arachidonyl-glycine inhibits the glycine transporter GlyT2, stimulates glycinergic neurotransmission, and provides analgesia in animal models of neuropathic and inflammatory pain. However, it is a relatively weak inhibitor with an IC50 of 9 μM and is subject to oxidation via cyclooxygenase, limiting its therapeutic value. In this paper we describe the synthesis and testing of a novel series of monounsaturated C18 and C16 acyl-glycine molecules as inhibitors of the glycine transporter GlyT2. We demonstrate that they are up to 28 fold more potent that N-arachidonyl-glycine with no activity at the closely related GlyT1 transporter at concentrations up to 30 μM. This novel class of compounds show considerable promise as a first generation of GlyT2 transport inhibitors.
Synthesis of antifungal alatanone and trineurone polyketides
Lewis, Alexander R.,Reber, Keith P.
supporting information, p. 1083 - 1086 (2018/03/23)
The antifungal polyketides alatanones A and B and trineurones A–E have been synthesized using a one-pot C-acylation reaction coupling 1,3-cyclohexanediones with the appropriate carboxylic acids. This key transformation is believed to proceed via initial carbodiimide-mediated O-acylation followed by a DMAP-catalyzed Claisen–Haase rearrangement, resulting in O to C acyl migration.
